Table 4:

Association of number of heart failure episodes in the first 2 years of follow-up with risk of chronic kidney disease progression and all-cause mortality among participants with chronic kidney disease

Decline in eGFR by 50% or progression to ESRD
			HR (95% CI)
Number of HF events, years 0 - 2	N at risk	N events	Unadjusted	Model 1	Model 2	Model 3
0	2868	827	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)
1	80	41	3.27 (2.39, 4.48)	2.61 (1.90, 3.59)	1.98 (1.43, 2.73)	1.93 (1.40, 2.67)
≥ 2	30	16	3.77 (2.30, 6.19)	3.41 (2.08, 5.60)	2.32 (1.41, 3.83)	2.14 (1.30, 3.54)
All-cause mortality
0	3380	698	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)
1	135	74	3.48 (2.74, 4.43)	3.41 (2.68, 4.35)	2.35 (1.83, 3.03)	2.20 (1.71, 2.84)
≥ 2	67	47	6.03 (4.48, 8.11)	5.81 (4.31, 7.83)	3.38 (2.48, 4.61)	3.06 (2.23, 4.18)

All HR with p-value <0.05

Model 1: age, sex, and race/ethnicity

Model 2: model 1 + diabetes, history of cardiovascular disease, use of lipid-lowering medications, smoking, systolic blood pressure, and body mass index

Model 3: model 2 + use of diuretics, angiotensin-converting-enzyme inhibitors/aldosterone receptor blockers, β-blockers